|Bid||72.35 x 300|
|Ask||72.37 x 700|
|Day's Range||72.08 - 72.79|
|52 Week Range||63.76 - 82.10|
|PE Ratio (TTM)||7.66|
|Dividend & Yield||2.08 (2.88%)|
|1y Target Est||N/A|
Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.